|
|
Article: $37M Addition Brings Archemix Series A Financing To $51.75M.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Archemix Corp. completed a Series A round that began more than a year ago, raising an additional $37 million to continue developing its aptamer therapeutics.
The company, founded in May 2001 with $8.25 million, extended its round in December with an additional $6.5 million, before continuing with the latest addition to raise a total of $51.75 million.
The money will be used, said Martin Stanton, Archemix president and a company founder, "most simply, to develop the aptamer therapeutics."
"We will develop drugs for ourselves, as well as develop partnerships," Stanton told BioWorld Today just before leaving to attend a ...
Related newspaper, magazine, and journal articles:
|